Abstracts tagged "Crystal-induced arthritis"

Abstract Number: 0815 • ACR Convergence 2023
Intermittent Fasting Reduces Crystal-induced Inflammation
Nghia Pham¹, Twinu Wilson Chirayath², Florence Castelli³, François Fenaille³, Anvi-Laetitia Nguyen³, François Brial⁴, Augustin Latourte⁴, Frédéric Lioté⁴, Pascal Richette⁵, Thomas Bardin⁶ and Hang Korng EA⁷, ¹INSERM 1132, BIOSCAR, Lariboisière hospital, Paris, France, ²INSERM, Paris, France, ³Laboratoire d’études du métabolisme des médicaments UMS 28, CEA Saclay, Gif-sur-Yvette, France, ⁴INSERM 1132, BIOSCAR, Paris, France, ⁵Lariboisière Hospital, Paris, France, ⁶Université de Paris Cité, Paris, France, ⁷INSERM-BIOSCAR, Paris, France
Background/Purpose: Inflammation induced by monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals depends on interleukin (IL)-1β activated by the NLRP3 inflammasome. The inflammatory response can…
Abstract Number: 1100 • ACR Convergence 2023
A Comparison of Characteristics of Patients with Crystalline and Septic Arthritis Confirmed by Synovial Fluid Analysis: Towards the Development of a Diagnostic Rule
Maria Salgado Guerrero¹, Mariana Urquiaga¹, Nishah Panchani² and Angelo Gaffo³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Tinsley Harrison Internal Medicine Residency Program, University of Alabama at Birmingham, Arlington, TX, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Distinguishing crystalline from septic arthritis is a common challenge in patients admitted with acute joint inflammation. Arthrocentesis for synovial fluid analysis is considered the…
Abstract Number: 1101 • ACR Convergence 2023
Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia
Maria-Luisa Peral-Garrido¹, Paula Boix-Navarro², Silvia Gómez-Sabater³, Rocío Caño-Alameda³, Alejandra Bermúdez-García⁴, Teresa Lozano⁴, Ruth Sanchez-Ortiga⁴, Miguel Perdiguero⁴, Elena Caro-Martínez⁵, Carolina Ruiz-García⁶, Eliseo Pascual⁴, Rubén Francés² and Mariano Andrés⁴, ¹Vinalopó University Hospital, Novelda, Spain, ²Miguel Hernandez University, San Juan de Alicante, Spain, ³Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ⁴Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ⁵San Vicente Hospital-HACLE, San Vicente del Raspeig, Spain, ⁶Campoamor Health Centre, Alicante, Spain
Background/Purpose: Whether the presence of subclinical monosodium urate (MSU) crystal deposition leads to a pro-inflammatory state in asymptomatic hyperuricemia (AH) is unknown. We aimed to…
Abstract Number: 1115 • ACR Convergence 2023
EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice
Peter Mandl¹, Maria-Antonietta D'Agostino², Victoria Navarro-Compán³, Irina Gessl¹, Garifallia Sakellariou⁴, Abhishek Abhishek⁵, Fabio Becce⁶, Nicola Dalbeth⁷, Hang-Korng Ea⁸, Emilio Filippucci⁹, Hilde Berner Hammer¹⁰, Annamaria Iagnocco¹¹, Annette De Thurah¹², Esperanza Naredo¹³, Sebastien Ottaviani¹⁴, Tristan Pascart¹⁵, Fernando Perez-Ruiz¹⁶, Irene Pitsillidou¹⁷, Fabian Proft¹⁸, Juergen Rech¹⁹, Wolfgang Schmidt²⁰, Luca Sconfienza²¹, Lene Terslev²², Brigitte Wildner²³, Pascal Zufferey²⁴ and Georgios Filippou²⁵, ¹Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Universita Cattolica del Sacro Cuore Rome, Courbevoie, France, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Department of Internal Medicine and Therapeutics, Università di Pavia, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, ⁵University of Nottingham, Nottingham, United Kingdom, ⁶Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁷University of Auckland, Auckland, New Zealand, ⁸Hôpital Lariboisière, APHP-Nord, Service de Rhumatologie, Université de Paris Cité, Paris, France, ⁹Polytechnic University of Marche, Jesi, Italy, ¹⁰Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway AND University of Oslo, Faculty of Medicine, Oslo, Norway, ¹¹University of Turin, Roma, Italy, ¹²Aarhus University Hospital, Aarhus, Denmark, ¹³Hospital Fundación, Madrid, Spain, ¹⁴Assistance Publique Hopitaux de Paris, Paris, France, ¹⁵Department of Rheumatology, Saint-Philibert Hospital, Lille Catholic University, Lille, France, ¹⁶Rheumatology Division, Osakidetza, OSI-EE Cruces, Cruces University Hospital, Barakaldo, Spain, ¹⁷EULAR Patient Research Partner, Executive Secretary of Cyprus League Against Rheumatism, Nicosia, Cyprus, ¹⁸Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ¹⁹University Clinic Erlangen, Erlangen, Germany, ²⁰Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ²¹Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano AND IRCCS Istituto Ortopedico Galeazzi, 20161, Milan, Italy, ²²Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ²³University Library, Medical University of Vienna, Vienna, Austria, ²⁴Rheumatology Department, University of Lausanne, CHUV, Lausenne, Switzerland, ²⁵IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy
Background/Purpose: The multifaceted clinical presentation in crystal-induced arthropathies (CiA) poses challenges to imaging. Our goal was to formulate evidence-based recommendations on the use of imaging…
Abstract Number: 1118 • ACR Convergence 2023
The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project
Silvia Sirotti¹, Charlotte Jauffret², Edoardo Cipolletta³, Daniele Cirillo⁴, Luca Ingrao⁴, Alessandro Lucia⁴, Antonella Adinolfi⁵, Debora Pireddu⁴, Emilio Filippucci⁶, Tristan Pascart², Sara Tedeschi⁷, Robert Terkeltaub⁸, Nicola Dalbeth⁹ and Georgios Filippou¹, ¹IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, ²Saint-Philibert Hospital, Lille Catholic University, Lille, France, ³Polytechnic University of Marche, Ancona, Italy, ⁴Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy, ⁵Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁶Polytechnic University of Marche, Jesi, Italy, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of California San Diego, San Diego, CA, ⁹University of Auckland, Auckland, New Zealand
Background/Purpose: Despite prior attempts at standardising terminology of calcium pyrophosphate deposition (CPPD) disease (including the 2011 EULAR recommendations for CPPD terminology and diagnosis), many different…
Abstract Number: 1121 • ACR Convergence 2023
Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
Roba Ghossan¹, Ouidade Aitisha Tabesh², Fouad Fayad², Pascal Richette³ and Thomas Bardin⁴, ¹COCHIN HOSPITAL, Paris, France, ²Hotel Dieu de France, Beirut, Lebanon, ³Lariboisière Hospital, Paris, France, ⁴Université de Paris Cité, Paris, France
Background/Purpose: To this date, a causal relationship between febuxostat and cardiovascular disease remains controversial as comparison between trials can be challenging and may lead to…
Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Mohnish Alishala¹, Stephen Calderon¹, Anyan Chen¹, Monica Guma², Christopher glass¹ and Isidoro Cobo¹, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…
Abstract Number: 0246 • ACR Convergence 2023
Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
Herbert Baraf¹, Alan Kivitz², Sheri Rhodes³, Sheldon Leung⁴, Olu Folarin⁴, Tania Gonzalez-Rivera⁵, Joanna Sobierska⁵, Jacquie Christie⁵, Anand Patel⁶, Wesley DeHaan⁴, Rehan Azeem⁴ and Peter Traber⁷, ¹The Center for Rheumatology and Bone Research, George Washington University, Rheumatology, Bethesda, MD, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Atlanta, GA, ⁴Selecta Biosciences, Inc., Watertown, MA, ⁵Swedish Orphan Biovitrum (Sobi), Stockholm, Sweden, ⁶Pioneer Research Solutions, Houston, TX, ⁷Selecta Biosciences, Gladwyne, PA
Background/Purpose: In patients with refractory gout, the inability to maintain serum uric acid (sUA) levels < 6 mg/dL leads to severe clinical manifestations for which…
Abstract Number: 1145 • ACR Convergence 2022
The Prostate Plays a Role in Serum Urate Levels and the Risk of Gout in Men
Mariana Urquiaga¹, Megan Leask¹, Nicholas Sumpter¹, Brooke Maxwell², Sara Lewis², Eric E. Kelley² and Tony Merriman³, ¹University of Alabama at Birmingham, Birmingham, AL, ²West Virginia University, Morgantown, WV, ³University of Otago, Dunedin, New Zealand
Background/Purpose: Men have higher serum urate (SU) and increased prevalence of gout compared to pre-menopausal women. Xanthine oxidoreductase (XOR), encoded by the XDH gene, is…
Abstract Number: 1791 • ACR Convergence 2022
Point-of-Care Multi-Energy Photon-Counting CT for Earlier Non-Invasive Diagnosis of Gout and Calcium Pyrophosphate Deposition Disease
Fabio Becce¹, Anais Viry², Damien Racine², David Rotzinger¹, Tristan Pascart³, Georgios Filippou⁴, Jérôme Damet² and Lucia Gallego Manzano², ¹Lausanne University Hospital (CHUV), Lausanne, Switzerland, ²Institute of Radiation Physics, Lausanne, Switzerland, ³Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁴Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy
Background/Purpose: While the definitive diagnosis of gout and calcium pyrophosphate deposition disease (CPPD) is still based on the identification of characteristic crystals in synovial fluid…
Abstract Number: 1801 • ACR Convergence 2022
High Frequency of Structural Damage in the Lower Spine of Patients with Chondrocalcinosis
Kalliopi Klavdianou¹, Jona Kasfeld², Martin Fruth³, Styliani Tsiami⁴, Juergen Braun⁵, Philipp Sewerin⁶, David Kiefer⁵ and Xenofon Baraliakos⁷, ¹'Asklepieion' General Hospital, Department of Rheumatology, Voula, Athens, Greece, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Blikk, Radiologie, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Calcium pyrophosphate dihydrate crystal deposition disease (CPPD, chondrocalcinosis) is known to affect fibrocartilaginous tissue in the large and smaller peripheral joints. The affection of…
Abstract Number: 1804 • ACR Convergence 2022
Raman Spectroscopy Integrated with Polarized Light Microscopy for Diagnosis of Crystallopathies
Tom Niessink¹, Matthijs Janssen², Cees Otto¹ and Tim Jansen³, ¹Medical Cell Biophysics group, University of Twente, Enschede, Netherlands, ²Rijnstate Hospital, Bennekom, Netherlands, ³Department of Rheumatology, VieCuri Medical Centre, Venlo, Netherlands
Background/Purpose: The current golden standard in diagnosing gout and calcium pyrophosphate deposition is polarized light microscopy (PLM). However, small crystal sizes, the presence of other…
Abstract Number: 1813 • ACR Convergence 2022
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Mary Grace Whelan¹, Keigo Hayashi² and Sara Tedeschi¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind these other forms of…
Abstract Number: 1817 • ACR Convergence 2022
Acute Coronary Syndrome in Calcium Pyrophosphate Deposition Disease Patients: A Cross-sectional Study from the National Inpatient Sample
Konstantinos Parperis¹ and Bikash Bhattarai², ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Valleywise Health, Phoenix, AZ
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common crystal-induced arthritis characterized by the deposition of calcium pyrophosphate crystals in the articular tissues. Acute CPP…
Abstract Number: 1825 • ACR Convergence 2022
Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study
Shay Brikman¹, Amir Bieber² and Reuven Mader¹, ¹Rheumatic Diseases Unit, Emek Medical Center, Afula, Israel, ²Emek Medical Center, Raanana, Israel
Background/Purpose: Prior studies have shown an association between chondrocalcinosis (CC) and vascular calcifications. In this study, we aimed to assess the presence of vascular calcifications…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].